Furthermore, the intrinsic vascular permeability characteristic of GBM may facilitate the selective accumulation of suitably engineered therapeutics, thereby enabling targeted modulation of NUCB2 within the GBM tumour microenvironment. This evidence concerns the gene NUCB2 and glioblastoma.